Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (1009)	6/11/1999 2:00:00 PM
From: Beltropolis Boy	Read Replies (1) \| Respond to of 1686

quod erat demonstrandum. ----- Biogen Announces 2-for-1 Stock Split June 11, 1999 01:40 PM CAMBRIDGE, Mass., June 11 /PRNewswire/ -- Biogen, Inc. (BGEN) today announced that its shareholders have approved an increase in the number of authorized shares of its Common Stock, which will enable the Company to complete a two-for-one stock split of the Common Stock. The stock split will be effected through a stock dividend of one share for each share of Common Stock outstanding. The stock dividend is payable on June 25, 1999, to stockholders of record at the close of business on June 11, 1999. As a result of the stock split, the number of outstanding shares of the Company's Common Stock will increase to approximately 149,789,754. The vote was taken at the Company's annual meeting, which was held today in Cambridge, MA. Jim Vincent, Biogen's Chairman and Chief Executive Officer, said, "We are pleased that our shareholders recognized the value of broadening Biogen's shareholder base and increasing the liquidity of the Company's shares. This action reflects our commitment to our stockholders and expresses our enthusiasm for the Company's opportunities for continued growth."

To: Harold Engstrom who wrote (1009)	6/11/1999 6:57:00 PM
From: P.M.Freedman	Read Replies (1) \| Respond to of 1686

Harold--Would you mind to share with us about what you know about Amevive and Antova? You said these two drugs from Biogen will be able to hit the market in 2001 and 2002, respectively. Thanks in advance!

To: Harold Engstrom who wrote (1009)	6/12/1999 10:26:00 PM
From: Walkingshadow	Read Replies (1) \| Respond to of 1686

Harold-- "Add in Amevive sales starting in 2001 and VLA4 royalties in 2002. Antova sales may begin in 2002 as well. Predictions about Amevive, Antova and VLA4 are just SWAGs now, but the consensus seems to be that all three have the potential to dwarf Avonex sales. There is more to the pipeline than these as well - CVT124 and 2 others." =========================================== Where do you get this information? Looking at their product pipeline on their website, I don't see "Amevive" or "Antova" at all. And the VLA-4 inhibitor is listed as being "Research" phase---far, far, away. Besides, there are many potential competing treatments for inflammation both on the market (COX-2 inhibitors, e.g.) and being developed. And CVT-124, a congestive heart failure drug in Phase II, will be introduced into an arena which already has a host of treatments available for the condition, and others are being developed. And that's assuming it is approved. I don't see clear sailing ahead, and I don't see that BGEN will have any additional source of revenue from products for quite some time, other than Hirulog. Walkingshadow